MedTrace Logo

Optimising Molecular Radionuclide Therapy

NCT04922801 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-03-08

No results posted yet for this study

Summary

This project will examine the role of the whole body, PET and SPECT imaging before, during and after radionuclide treatment for 177Lu-Dotatate therapy, whole body and SPECT imaging for 131-I for thyroid cancer therapy, and whole-body imaging for 131I for hyperthyroidism therapy. Whole-body and SPECT images will be linked to personal dosimeter readings to determine whether

* Current radiation protection advice for patients receiving radionuclide treatment is appropriate.
* Radiopharmaceutical retention and/or SUV change in patients undergoing repeated radionuclide treatments.
* Data combined from early (quantitative imaging) and late (whole-body dose rate measurements) could support individual treatment planning for patients undergoing repeated cycles of molecular therapy.

Conditions

Interventions

DIAGNOSTIC_TEST

Nuclear Medicine whole-body

Gamma-Camera Whole-body scan at 24-48 hour post-Molecular Radiotherapy (MRT).

DIAGNOSTIC_TEST

SPECT/CT imaging.

SPECT/CT scan at 24-48 hr post MRT

DIAGNOSTIC_TEST

PET/CT imaging.

3-6 months Pre and post-therapy PET/CT imaging

DEVICE

Patient-led radiation monitor (SELFIE)

Following MRT administration, a standard whole body dosimetry measurement will be taken by medical physicist at 1 and 2 meters distance. The patient will begin to take SELFIE readings at the same time under supervision so that their records can be compared with the physicists' results. After 28 days, patients will be asked to return the diary sheet and SELFIE monitor by post to GSTTFT in a pre-paid, pre-addressed envelope. On completion of the 28 day exercise, patients will be asked to complete and return a feedback questionnaire.

DIAGNOSTIC_TEST

LAB TEST

Biochemistry, haematology and tumour markers blood tests pre, post and during MRT.

Sponsors & Collaborators

Principal Investigators

  • Valerie Lewington, Professor · King's College London

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-09
Primary Completion
2022-10-20
Completion
2022-11-05

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04922801 on ClinicalTrials.gov